These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33917250)

  • 1. Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
    Ziouti F; Rummler M; Steyn B; Thiele T; Seliger A; Duda GN; Bogen B; Willie BM; Jundt F
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
    Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
    Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease.
    Rummler M; Ziouti F; Bouchard AL; Brandl A; Duda GN; Bogen B; Beilhack A; Lynch ME; Jundt F; Willie BM
    Acta Biomater; 2021 Jan; 119():247-258. PubMed ID: 33130307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Marine J; Miranda M; Azaryan A; Yu X; Nava-Parada P; Mei J; Kipps TJ
    Haematologica; 2016 Jul; 101(7):e295-8. PubMed ID: 27151992
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone mechanical properties were altered in a mouse model of multiple myeloma bone disease.
    Rummler M; Ziouti F; Snyder L; Zimmermann EA; Lynch M; Donnelly E; Wagermaier W; Jundt F; Willie BM
    Biomater Adv; 2025 Jan; 166():214047. PubMed ID: 39303656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase: oncotarget in myeloma.
    Tai YT; Anderson KC
    Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
    Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
    Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
    Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.
    Hofgaard PO; Jodal HC; Bommert K; Huard B; Caers J; Carlsen H; Schwarzer R; Schünemann N; Jundt F; Lindeberg MM; Bogen B
    PLoS One; 2012; 7(12):e51892. PubMed ID: 23284805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292.
    Labenski M; Voortman L; Medikonda AP; Sherratt PJ; Corin AF
    J Pharmacol Exp Ther; 2021 Nov; 379(2):166-174. PubMed ID: 34373353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.
    Yang J; He J; Wang J; Cao Y; Ling J; Qian J; Lu Y; Li H; Zheng Y; Lan Y; Hong S; Matthews J; Starbuck MW; Navone NM; Orlowski RZ; Lin P; Kwak LW; Yi Q
    Leukemia; 2012 Sep; 26(9):2114-23. PubMed ID: 22425892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate.
    N'Diaye M; Libouban H; Aguado E; Bouvard B; Audran M; Chappard D
    Micron; 2015 Jan; 68():107-114. PubMed ID: 25464148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.
    Schwarzer R; Nickel N; Godau J; Willie BM; Duda GN; Schwarzer R; Cirovic B; Leutz A; Manz R; Bogen B; Dörken B; Jundt F
    Blood Cancer J; 2014 Jun; 4(6):e217. PubMed ID: 24927406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies for bone disease.
    Roodman GD
    Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
    Fancher KM; Pappacena JJ
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):507-515. PubMed ID: 32940733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.